Literature DB >> 21283079

Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization.

Takatoshi Sato1, Yoshitaka Iso, Taro Uyama, Keisuke Kawachi, Kohei Wakabayashi, Yasutoshi Omori, Teruko Soda, Makoto Shoji, Shinji Koba, Shin-Ichiro Yokoyama, Noboru Fukuda, Satoshi Saito, Takashi Katagiri, Youichi Kobayashi, Youichi Takeyama, Akihiro Umezawa, Hiroshi Suzuki.   

Abstract

Few reports have examined the effects of adult bone marrow multipotent stromal cells (MSCs) on large animals, and no useful method has been established for MSC implantation. In this study, we investigate the effects of MSC infusion from the coronary vein in a swine model of chronic myocardial infarction (MI). MI was induced in domestic swine by placing beads in the left coronary artery. Bone marrow cells were aspirated and then cultured to isolate the MSCs. At 4 weeks after MI, MSCs labeled with dye (n=8) or vehicle (n=5) were infused retrogradely from the anterior interventricular vein without any complications. Left ventriculography (LVG) was performed just before and at 4 weeks after cell infusion. The ejection fraction (EF) assessed by LVG significantly decreased from baseline up to a follow-up at 4 weeks in the control group (P<0.05), whereas the cardiac function was preserved in the MSC group. The difference in the EF between baseline and follow-up was significantly greater in the MSC group than in the control group (P<0.05). The MSC administration significantly promoted neovascularization in the border areas compared with the controls (P<0.0005), though it had no affect on cardiac fibrosis. A few MSCs expressed von Willebrand factor in a differentiation assay, but none of them expressed troponin T. In quantitative gene expression analysis, basic fibroblast growth factor and vascular endothelial growth factor (VEGF) levels were significantly higher in the MSC-treated hearts than in the controls (P<0.05, respectively). Immunohistochemical staining revealed VEGF production in the engrafted MSCs. In vitro experiment demonstrated that MSCs significantly stimulated endothelial capillary network formation compared with the VEGF protein (P<0.0001). MSC infusion via the coronary vein prevented the progression of cardiac dysfunction in chronic MI. This favorable effect appeared to derive not from cell differentiation, but from enhanced neovascularization by angiogenic factors secreted from the MSCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21283079     DOI: 10.1038/labinvest.2010.202

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  25 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

Review 2.  Human coronary venous anatomy: implications for interventions.

Authors:  Julianne H Spencer; Sara E Anderson; Paul A Iaizzo
Journal:  J Cardiovasc Transl Res       Date:  2013-01-11       Impact factor: 4.132

3.  Bone tissue engineering via human induced pluripotent, umbilical cord and bone marrow mesenchymal stem cells in rat cranium.

Authors:  Ping Wang; Xian Liu; Liang Zhao; Michael D Weir; Jirun Sun; Wenchuan Chen; Yi Man; Hockin H K Xu
Journal:  Acta Biomater       Date:  2015-02-21       Impact factor: 8.947

4.  Flk-1⁺Sca-1⁻ mesenchymal stem cells: functional characteristics in vitro and regenerative capacity in vivo.

Authors:  Yugang Li; Enshan Pan; Yu Wang; Xiaoguang Zhu; Anyang Wei
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Human Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia.

Authors:  Chuan-Bin Liu; He Huang; Ping Sun; Shi-Ze Ma; An-Heng Liu; Jian Xue; Jin-Hui Fu; Yu-Qian Liang; Bing Liu; Dong-Ying Wu; Shuang-Hong Lü; Xiao-Zhong Zhang
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

6.  Cotransplantation of human umbilical cord-derived mesenchymal stem cells and umbilical cord blood-derived CD34⁺ cells in a rabbit model of myocardial infarction.

Authors:  Tong Li; Qunxing Ma; Meng Ning; Yue Zhao; Yuelong Hou
Journal:  Mol Cell Biochem       Date:  2013-10-29       Impact factor: 3.396

7.  Distinct mobilization of circulating CD271+ mesenchymal progenitors from hematopoietic progenitors during aging and after myocardial infarction.

Authors:  Yoshitaka Iso; Sayaka Yamaya; Takatoshi Sato; Charla N Poole; Keiichi Isoyama; Masaru Mimura; Shinji Koba; Youichi Kobayashi; Youichi Takeyama; Jeffrey L Spees; Hiroshi Suzuki
Journal:  Stem Cells Transl Med       Date:  2012-06-05       Impact factor: 6.940

8.  Increased mobilization of mesenchymal stem cells in patients with essential hypertension: the effect of left ventricular hypertrophy.

Authors:  Maria E Marketou; Fragiskos I Parthenakis; Athanasia Kalyva; Charalampos Pontikoglou; Spyros Maragkoudakis; Joanna E Kontaraki; Evangelos A Zacharis; Gregory Chlouverakis; Alexandros Patrianakos; Helen A Papadaki; Panos E Vardas
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-10-20       Impact factor: 3.738

9.  Markers for characterization of bone marrow multipotential stromal cells.

Authors:  Sally A Boxall; Elena Jones
Journal:  Stem Cells Int       Date:  2012-05-14       Impact factor: 5.443

10.  Comparing the angiogenic potency of naïve marrow stromal cells and Notch-transfected marrow stromal cells.

Authors:  Mo Dao; Ciara C Tate; Michael McGrogan; Casey C Case
Journal:  J Transl Med       Date:  2013-03-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.